|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 205.20 EUR | -1.06% |
|
-3.80% | +8.74% |
| 12-12 | U.S. Futures Mixed, European Stocks Up | DJ |
| 12-10 | MedTech Stocks Diverge Following Exane Report: 'A Split 2026' | DP |
| Capitalization | 19.97B 23.44B 18.65B 17.55B 32.31B 2,123B 35.29B 218B 84.44B 1,001B 87.94B 86.09B 3,651B | P/E ratio 2025 * |
61.6x | P/E ratio 2026 * | 45.8x |
|---|---|---|---|---|---|
| Enterprise value | 22.06B 25.89B 20.61B 19.39B 35.69B 2,345B 38.99B 241B 93.29B 1,106B 97.16B 95.11B 4,033B | EV / Sales 2025 * |
7.41x | EV / Sales 2026 * | 6.72x |
| Free-Float |
30.28% | Yield 2025 * |
0.4% | Yield 2026 * | 0.5% |
Last Transcript: Sartorius Stedim Biotech
| 1 day | -1.06% | ||
| 1 week | -3.80% | ||
| Current month | -1.01% | ||
| 1 month | +6.07% | ||
| 3 months | +20.95% | ||
| 6 months | +3.09% | ||
| Current year | +8.74% |
| 1 week | 201.6 |  | 214.9 |
| 1 month | 182.75 | | 217.2 |
| Current year | 148.75 | | 239.8 |
| 1 year | 148.75 | | 239.8 |
| 3 years | 139.1 | | 358.8 |
| 5 years | 139.1 | | 551 |
| 10 years | 50.1 | | 551 |
| Manager | Title | Age | Since |
|---|---|---|---|
René Fáber
CEO | Chief Executive Officer | 50 | 2023-03-27 |
| Chief Tech/Sci/R&D Officer | 61 | 2011-09-07 | |
Petra Kirchhoff
IRC | Investor Relations Contact | 56 | - |
| Director | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 64 | 2015-04-06 | |
Susan Dexter
BRD | Director/Board Member | 69 | 2015-04-06 |
Lothar Kappich
BRD | Director/Board Member | 68 | 2017-09-13 |
| Name | Weight | AuM | Varia. Jan 1. | Investor |
|---|---|---|---|---|
 | 0.42% | 26 M€ | +12.27% | - |
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
| -1.06% | -3.80% | +5.72% | -37.11% | 23.44B | |
| +1.77% | +0.30% | +10.65% | +12.49% | 218B | |
| +0.12% | -1.47% | +21.08% | +24.62% | 128B | |
| +0.44% | +1.87% | +48.98% | +109.66% | 67.12B | |
| +0.23% | +3.57% | -10.94% | -20.93% | 57.34B | |
| +1.79% | -0.02% | +18.70% | +72.96% | 51.86B | |
| -2.87% | +2.24% | -13.25% | -43.99% | 26.12B | |
| -0.28% | -4.36% | +17.54% | +26.48% | 24.71B | |
| +0.63% | -2.38% | -24.21% | +16.21% | 21.9B | |
| +0.52% | -2.89% | +9.79% | -5.53% | 20.8B | |
| Average | +0.13% | -0.69% | +8.41% | +15.49% | 63.95B | |
| Weighted average by Cap. | +0.71% | -0.07% | +13.37% | +22.98% |
| 2025 * | 2026 * | |
|---|---|---|
| Net sales | 2.98B 3.49B 2.78B 2.62B 4.81B 316B 5.26B 32.44B 12.59B 149B 13.11B 12.83B 544B | 3.25B 3.82B 3.04B 2.86B 5.27B 346B 5.75B 35.48B 13.76B 163B 14.33B 14.03B 595B |
| Net income | 317M 373M 297M 279M 514M 33.75B 561M 3.46B 1.34B 15.91B 1.4B 1.37B 58.04B | 433M 508M 404M 380M 700M 45.99B 765M 4.72B 1.83B 21.68B 1.91B 1.87B 79.09B |
| Net Debt | 2.09B 2.46B 1.96B 1.84B 3.39B 223B 3.7B 22.82B 8.85B 105B 9.22B 9.03B 383B | 1.9B 2.24B 1.78B 1.67B 3.08B 202B 3.37B 20.76B 8.05B 95.43B 8.39B 8.21B 348B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 25-12-12 | 205.20 € | -1.06% | 55,177 |
| 25-12-11 | 207.40 € | -1.00% | 39,699 |
| 25-12-10 | 209.50 € | +0.67% | 72,208 |
| 25-12-09 | 208.10 € | -1.61% | 60,311 |
| 25-12-08 | 211.50 € | -0.84% | 55,200 |
Real-time Euronext Paris, December 12, 2025 at 11:55 am
More quotes
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Global Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Global Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite), and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of the rankings based on the following ratings: Capital Efficiency (Composite), Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- DIM Stock
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition